Skip to main content
Abbisko Cayman Limited logo

Abbisko Cayman Limited — Investor Relations & Filings

Ticker · 2256 ISIN · KYG0028A1085 LEI · 655600UAX2YV03PRXN31 HKEX Manufacturing
Open in API
Filings indexed 402 across all filing types
Latest filing 2025-05-02 Transaction in Own Shar…
Country KY Cayman Islands
Listing HKEX 2256

About Abbisko Cayman Limited

http://www.abbisko.com

Abbisko Cayman Limited is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule therapies. The company leverages a robust in-house R&D engine and a multi-dimensional discovery platform to advance a rich pipeline focused primarily on oncology, encompassing both precision-oncology and immuno-oncology candidates. Key product candidates include pimicotinib, which has shown positive topline results for the treatment of tenosynovial giant cell tumor (TGCT). Abbisko aims to develop novel treatments that address critical unmet medical needs for patients globally.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Returns
Transaction in Own Shares Classification · 1% confidence The document is a Hong Kong Stock Exchange “Next Day Disclosure Return” (Form FF305) detailing changes in issued shares, repurchases of shares held as treasury shares, and related share buyback information under Main Board Rule 13.25A/10.06 et al. It is neither an AGM presentation nor a financial report like a 10-K or interim report, but a disclosure of the company’s own share transactions. This matches the “Transaction in Own Shares” category (POS).
2025-05-02 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2025
Regulatory Filings Classification · 1% confidence The document is HKEX Form FF301 – a monthly statutory return detailing movements in authorised share capital, issued and treasury shares, share option exercises, repurchases, confirmations, etc. under Chapter 19B of the Listing Rules. It is a routine regulatory submission with detailed content, not a simple notice that a report is attached (so not RPA). It is not an annual, interim, or earnings report, nor a one‐off management or board announcement. It is best classified under the general Regulatory Filings fallback.
2025-05-02 English
Next Day Disclosure Returns
Transaction in Own Shares Classification · 1% confidence The document is a "Next Day Disclosure Return" filed under HKEx Main Board/GEM rules (Form FF305), providing detailed tables of the issuer’s share repurchases, treasury share transactions, and related confirmations. It is clearly reporting the company’s transactions in its own shares (repurchases and treasury share changes). This corresponds to our category for “Transaction in Own Shares.”
2025-04-30 English
Next Day Disclosure Returns
Transaction in Own Shares Classification · 1% confidence The document is a mandatory “Next Day Disclosure Return” (Form FF305) filed under the Hong Kong Stock Exchange Listing Rules, detailing share repurchases, treasury share changes, and on-market sales. It is not an earnings release, annual report, or proxy. It specifically reports the company’s own share transactions (repurchases and treasury share movements). Therefore, it fits the Transaction in Own Shares category.
2025-04-29 English
Next Day Disclosure Returns
Transaction in Own Shares Classification · 1% confidence The document is an HKEx “Next Day Disclosure Return” (Form FF305) under Main Board Rule 13.25A/GEM Rule 17.27A, showing changes in issued shares, treasury shares, and detailed share repurchase data. It is a formal regulatory filing specifically reporting the company’s transactions in its own shares (repurchases and on-market sales of treasury shares). This matches the definition for a Transaction in Own Shares (POS).
2025-04-28 English
VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS PRESENTS FOUR LATE-BREAKING PRE-CLINICAL RESEARCH RESULTS ON ABSK112 (EGFR EXON20INS), ABSK131 (PRMT5*MTA), AND ABK-KRAS-1 (PAN-KRAS) AT 2025 AACR CONFER
Regulatory Filings Classification · 1% confidence The document is a voluntary press release under Hong Kong listing rules announcing pre-clinical research results presented at a scientific conference. It contains no financial results, management changes, capital transactions, or voting information. It is not an investor presentation or report publication announcement. Therefore it falls under general regulatory announcements that do not fit a more specific category (Regulatory Filings).
2025-04-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.